Ali Health's stock surged 5.00% during intraday trading on Friday, significantly outperforming the broader market.

The medical e-commerce sector staged a collective rebound, providing broad-based support. Additionally, the innovative drug first-launch platform effect continues to gain momentum, with specific new drugs exclusively debuting on Ali Health's platform, reinforcing the company's positioning as a premier launch destination for new and specialty drugs.

The company recently reported strong fiscal year results with net profit growth of 35.2% year-over-year, while announcing a proposed share buyback authorization and dividend distributions, signaling continued commitment to shareholder returns.